ClinicalTrials.gg
CompletedNCT03471663Updated Jan 8, 2024

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

A Phase 1 interventional study of D-0502 and palbociclib in Breast Cancer, sponsored by InventisBio Co., Ltd. Completed at 15 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate preliminary anti-tumor activities in women with advanced or metastatic ER-positive, HER2-negative breast cancer.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

This study's enrollment of 200 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -proven, ER-positive, -negative locally advanced, inoperable, and/or breast cancer.
  2. Female patients with menopausal status:

    i. status defined as meeting at least one of the following criteria:

    1. Have undergone a bilateral oophorectomy any time in life;
    2. Age ≥60 years, or
    3. Age \<60 years but have cessation of regular menses ≥12 months with follicle stimulating hormone (FSH) value >40 milli-international units per milliliter (mIU/mL) and an estradiol value \<40 picograms per milliliter (pg/mL) (140 picomoles per liter [pmol/L]).

    ii. Premenopausal or perimenopausal concurrently given a luteinizing hormone-releasing hormone (LHRH) agonist starting at least 4 weeks before the start of trial therapy and is planned to continue LHRH agonist during the study.

  3. Patients meeting all the following criteria:

    1. Has had at least 6 months of endocrine therapy for metastatic ER+ breast cancer prior to disease progression;
    2. Limited number of prior chemotherapy, endocrine therapy, and targeted therapy for advanced or metastatic disease
    3. Radiological or objective evidence of disease progression on or after the last systemic therapy prior to starting current study treatment.
    4. For phase Ia: Not eligible for standard therapy that would confer clinical benefit to the patient.

Exclusion criteria

Exclusion Criteria:

  1. Patients with prior anticancer or drug treatment within the following windows are excluded:
  2. Participants with prior anticancer or investigational drug treatment within the following windows are excluded:

    1. Any anti-cancer therapy (including endocrine therapy, chemotherapy, targeted therapy, etc.) less than 30 days before first dose of study treatment.
    2. Any investigational drug therapy less than 28 days or 4 half-lives (whichever is shorter) prior to first dose of study treatment.
  3. Patients with untreated or symptomatic or progressive central nervous system (CNS) .

    • Other protocol defined inclusion/exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    D-0502

    D-0502

    Drug: D-0502

  • Experimental
    D-0502 in combination with palbociclib

    D-0502 in combination with palbociclib

    Drug: D-0502 · Drug: palbociclib

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria

    Time frame: Approximately 2 years

Secondary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: Cycle 1 (28 days)

  2. Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Cycle 1 (28 days)

  3. Time of maximum observed concentration (Tmax)

    Time frame: Cycle 1 (28 days)

  4. Objective response rate (ORR)

    Time frame: up to 12 months

  5. Progression free survival (PFS)

    Time frame: up to 12 months

07

Study locations

15 sites
  • Local Institution
    Fresno, California 93720, United States
  • Local Institution
    Aurora, Colorado 80012, United States
  • Local Institution
    New Haven, Connecticut 06511, United States
  • Local Institution
    Boston, Massachusetts 02114, United States
  • Local Institution
    Eugene, Oregon 97401, United States
  • Local Institution
    Greenville, South Carolina 29605, United States
  • Local Institution
    Nashville, Tennessee 37203-1619, United States
  • Local Institution
    Dallas, Texas 75246, United States
  • Local Institution
    San Antonio, Texas 78217, United States
  • Local Institution
    San Antonio, Texas 78229, United States
  • Local Institution
    Tyler, Texas 75702, United States
  • Local Institution
    Beijing, Chaoyang District 100021, China
  • Local Institution
    Guangzhou, Guangdong, China
  • Local Institution
    Changsha, Hunan Provence, China
  • Local Institution
    Shenyang, Liaoning 110042, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2023, 67 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 67 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2018
First posted
Mar 20, 2018
StartActual
Mar 18, 2018
Primary completionActual
Oct 18, 2023
CompletionActual
Oct 18, 2023
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03471663
Responsible party
Sponsor
First posted
Mar 20, 2018
Start date
Mar 18, 2018
Primary completion
Oct 18, 2023
Completion
Oct 18, 2023
Last update
Jan 8, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taragarestrant

Start the discussion